Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aptus Pharma's Days Sales Outstanding for the
six
months ended in Mar. 2026 was 81.71.
Aptus Pharma's Days Inventory for the
six
months ended in Mar. 2026 was 140.38.
Aptus Pharma's Days Payable for the
six
months ended in Mar. 2026 was 82.64.
Therefore, Aptus Pharma's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2026 was 139.45.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Aptus Pharma Cash Conversion Cycle Related Terms
Aptus Pharma Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Aptus Pharma's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544529 vs MCK, COR, CAH: Cash Conversion Cycle Comparison
For the Medical Distribution subindustry, Aptus Pharma's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptus Pharma Cash Conversion Cycle vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Aptus Pharma's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Aptus Pharma's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Aptus Pharma's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptus Pharma (BOM:544529) has a Cash Conversion Cycle of 139.45 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Aptus Pharma and its competitors.
Is Aptus Pharma's Cash Conversion Cycle too high?
Aptus Pharma's current Cash Conversion Cycle is 139.45. The Medical Distribution industry median Cash Conversion Cycle is 52.15. Aptus Pharma's value of 139.45 is 167.4% above this industry median. Overall, Aptus Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Aptus Pharma's Cash Conversion Cycle compare to MCK and COR?
Aptus Pharma's Cash Conversion Cycle of 139.45 can be compared against companies in the Medical Distribution industry. The industry median Cash Conversion Cycle is 52.15. Aptus Pharma's value of 139.45 is 167.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Distribution company?
The median Cash Conversion Cycle among Medical Distribution companies is 52.15, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aptus Pharma's current Cash Conversion Cycle of 139.45 is 167.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Aptus Pharma and its competitors. For the Medical Distribution industry, the median Cash Conversion Cycle is 52.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aptus Pharma's current Cash Conversion Cycle is 139.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptus Pharma stock overvalued right now?
Aptus Pharma (BOM:544529) has a current Cash Conversion Cycle of 139.45. The current Cash Conversion Cycle is 139.45 and 167.4% above the Medical Distribution industry median of 52.15. Aptus Pharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Aptus Pharma (BOM:544529), the current Cash Conversion Cycle is 139.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations. It operates through a contract manufacturing model. The group provides a diverse range of pharmaceutical products catering to various therapeutic categories, including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, lipid-lowering, and general wellness products. These are offered across a variety of dosage forms, such as tablets, capsules, softgels, syrups, suspensions, injections, ointments, creams, balms, drops, lotions, vials, powders, gels, and sachets.
18GF Score
Get the complete analysis for BOM:544529
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544529 has been successfully added to your 
